title: Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study).
abstract: OBJECTIVE
  Combined hyperlipidaemia is a common and highly atherogenic lipid phenotype with multiple lipoprotein abnormalities that are difficult to normalise with single-drug therapy. The ATOMIX multicentre, controlled clinical trial compared the efficacy and safety of atorvastatin and bezafibrate in patients with diet-resistant combined hyperlipidaemia.
  
  
  METHODS
  Following a 6-week placebo run-in period, 138 patients received atorvastatin 10mg or bezafibrate 400mg once daily in a randomised, double-blind, placebo-controlled trial. To meet predefined low-density lipoprotein-cholesterol (LDL-C) target levels, atorvastatin dosages were increased to 20mg or 40mg once daily after 8 and 16 weeks, respectively.
  
  
  RESULTS
  After 52 weeks, atorvastatin achieved greater reductions in LDL-C than bezafibrate (percentage decrease 35 vs 5; p < 0.0001), while bezafibrate achieved greater reductions in triglyceride than atorvastatin (percentage decrease 33 vs 21; p < 0.05) and greater increases in high-density lipoprotein-cholesterol (HDL-C) [percentage increase 28 vs 17; p < 0.01 ]. Target LDL-C levels (according to global risk) were attained in 62% of atorvastatin recipients and 6% of bezafibrate recipients, and triglyceride levels <200 mg/dL were achieved in 52% and 60% of patients, respectively. In patients with normal baseline HDL-C, bezafibrate was superior to atorvastatin for raising HDL-C, while in those with baseline HDL-C <35 mg/dL, the two drugs raised HDL-C to a similar extent after adjustment for baseline values. Both drugs were well tolerated.
  
  
  CONCLUSIONS
  The results show that atorvastatin has an overall better efficacy than bezafibrate in concomitantly reaching LDL-C and triglyceride target levels in combined hyperlipidaemia, thus supporting its use as monotherapy in patients with this lipid phenotype.
authors: Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic i Provincial, Barcelona, Spain, eros@clinic.ub.es.
authors: Emilio
authors: E
authors: Ros
authors: Josefina
authors: J
authors: Oliván
authors: José M
authors: JM
authors: Mostaza
authors: Miquel
authors: M
authors: Vilardell
authors: Xavier
authors: X
authors: Pintó
authors: Fernando
authors: F
authors: Civeira
authors: A
authors: A
authors: Hernández
authors: Pedro
authors: P
authors: Marqués da Silva
authors: A
authors: A
authors: Rodriguez-Botaro
authors: Daniel
authors: D
authors: Zambón
authors: Joan
authors: J
authors: Lima
authors: José A
authors: JA
authors: Gómez-Gerique
authors: Cristina
authors: C
authors: Díaz
authors: Rosa
authors: R
authors: Arístegui
authors: José M
authors: JM
authors: Sol
authors: Gonzalo
authors: G
authors: Hernández